Overview
- Generation of cell lines with CRISPR-mediated gene knockout, mutation knocking
- Genome-wide screening for target identification and validation
- Human and mouse CRISPR knockout libraries
- Human CRISPR activation libraries
- Fast generation of GEMMs for genetic disease
- Gene therapy
In vivo CRISPR animal models and services
High Efficiency Genome Editing Service for Drug Discovery
From genome editing to disease models and PK-PD-efficacy studies
In Vivo CRISPR Platform for Rare Disease
- Well-established in vivo gene editing platform in rodent
- Generation of genetically engineered animal models (GEAM) for drug discovery in rare disease
- 30+ knockin and knockout mouse lines generated last year
Efficacy Evaluation and MoA Research Platform
- Well-established in vitro, ex vivo and in vivo bioassay platforms
- Multiple routes for drug administration, animal and tissue manipulation and histopathology
Knockout Services
- CRISPR/CAS9 based knockout in mouse, rat
- ES cell based knockout in mouse
Knockin Services
- CRISPR/CAS9 based knockin in mouse, rat
- ES cell based knocking in mouse
Humanization Services
- In situ replace mouse gene with matched human exons or introns
- Express human cDNA under the control of mouse promoter
Transgenic Services
- Random integration into genome
- Targeted transgene into Rosa26 or other site
Genotyping and Phenotyping Services
- Analyze the genotype of mice and cells by PCR, Southern Blot or NGS
- Characterization of disease mouse models
Other Services
- In vitro fertilization
- Embryo and sperm cryopreservation
Compliance and Accreditations
- AAALAC accredited facility
- OECD – received a statement of GLP compliance from the Belgium regulatory authorities
- Chinese SFDA – received certificate of GLP compliance
- WuXi has conducted IND and NDA enabling studies for submission to the US FDA
